Results 81 to 90 of about 14,157,417 (290)

Disposición UNRN-SE Nº 07/2025. Asignar [PDF]

Fil: Secretaría de Extensión (E). Universidad Nacional de Río Negro. Río Negro, ArgentinaDisposición UNRN-SE Nº 07/2025. Asignar la cada una de las Subsecretarias de Extensión de Sedes, para garantizar las actividades extensionista en el marco del ...
Secretaría de Extensión (E)
core  

A phase 1 study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of PF‐07261271 in healthy participants

British Journal of Clinical Pharmacology, EarlyView.
Aim There is an unmet need for more effective therapies in inflammatory bowel disease (IBD). A single drug that blocks multiple distinct pathogenic pathways may offer therapeutic benefit superior to current monotherapies. PF‐07261271, a bispecific antibody targeting both the p40 subunit of interleukin‐12/23 and tumour necrosis factor‐like cytokine 1A ...
Srividya Neelakantan, Christopher Banfield, Kenneth Hung, Anna Sapone, Vivek Pradhan, Yuxi Zhao, Dana Parsons‐Rich, Grace Lee, Bryce G. Johnson, Elena Peeva, Michael S. Vincent, Valerie M. Clerin   +11 more
wiley   +1 more source

Disposición UNRN-SE Nº 11/2025. Sustituir el Anexo I de la Disposición UNRN-SE N° 10/2025. [PDF]

Fil: Secretaría de Extensión (E). Universidad Nacional de Río Negro. Río Negro, ArgentinaDisposición UNRN-SE Nº 11/2025.
Secretaría de Extensión (E)
core  

S. aureus colonization and clinical symptoms remain stable upon topical XZ.700 treatment: Results of a double‐blind randomized clinical trial in patients with mild to moderate atopic dermatitis

British Journal of Clinical Pharmacology, EarlyView.
Aim Recovering dysbiosis may improve atopic dermatitis (AD) symptoms. XZ.700 is a recombinant chimeric endolysin that specifically targets Staphylococcus aureus and could be a new treatment option for patients with AD. The aim of this first‐in‐human study was to evaluate the safety, tolerability and efficacy of topical XZ.700 and explore the ...
Laura W. J. van der Meulen, Menthe E. Bergmans, Salma Assil, Naomi Klarenbeek, Marieke L. de Kam, Alexa J. Tibboel, Thorsten Brach, Bjorn L. Herpers, Johan Frieling, Vincent de Jong, Benthe Freyee, Martijn B. A. van Doorn, Robert Rissmann, Tessa Niemeyer–van der Kolk   +13 more
wiley   +1 more source

A Multicenter, Open‐Label, Phase 2 Trial Comparing Crizanlizumab Combined With Standard Therapy to Standard Therapy Alone on Renal Function in Patients With Sickle Cell Nephropathy (STEADFAST)

American Journal of Hematology, EarlyView.
Kenneth I. Ataga, Pablo Bartolucci, Santosh L. Saraf, Vimal K. Derebail, Adlette Inati, Jeffrey D. Lebensburger, Laurie DeBonnett, Rodolfo D. Cancado, Claire C. Sharpe   +8 more
wiley   +1 more source

Effect of esomeprazole on the pharmacokinetics of vepdegestrant, a PROteolysis TArgeting Chimera oestrogen receptor degrader, in healthy participants

British Journal of Clinical Pharmacology, EarlyView.
Aims The aim of this study is to evaluate the effects of multiple doses of esomeprazole, a strong proton pump inhibitor and acid‐reducing agent, on the pharmacokinetics and safety of vepdegestrant, a PROteolysis TArgeting Chimera oestrogen receptor degrader.
Lana Tran, Naihan Chen, Jennifer A. Winton, Kyle T. Matschke, Smita P. Goodman, Kimberly C. Lee, Yuanyuan Zhang, Weiwei Tan   +7 more
wiley   +1 more source

Hashimoto Tiroiditli Hastalarda Bakır, Demir, Çinko, Selenyum Düzeyleri ve Cu/Se, Cu/Zn, Fe/Se, Fe/Zn Oranlarının Araştırılması

Sakarya Tıp Dergisi, 2018
Amaç: Bu çalışmanın amacı, Hashimoto tiroiditi (HT) etiyopatogenezinde selenyum (Se) demir (Fe), çinko (Zn) ve bakır (Cu) eser elementlerinin serum düzeylerindeki ve oranlarındaki değişimlerinin belirlenmesi ve bu parametreler arasındaki olası ilişkinin ...
Birsen Aydemir, Nurten Bahtiyar Bahtiyar, Esra Ertan, Sevgin Değirmencioğlu, Nilgun Dilaveroğlu, Ayse Erdogan Çakar, Hakan Cinemre, Fatma Behice Serinkan Cinemre   +7 more
doaj   +1 more source

First‐in‐human, phase I, randomized, safety, pharmacokinetic, food‐effect and pharmacodynamic study of a tyrosine kinase 2/Janus kinase 1 inhibitor, SDC‐1801

British Journal of Clinical Pharmacology, EarlyView.
Aim The purpose of this study is to evaluate safety, tolerability, pharmacokinetics (PK), food‐effect (FE) and pharmacodynamics (PD) of an oral tyrosine kinase‐2 (TYK2)/Janus kinase‐1 (JAK1) inhibitor, SDC‐1801, in healthy adult participants. Methods This first‐in‐human study randomized 95 male and female participants.
Chris Brearley, Sam Francis, John Reader, Judi Proctor   +3 more
wiley   +1 more source

Metalliferous jurassic rocks of the Fan-Y agnob syneclise (Central Tajikistan)

Известия высших учебных заведений: Геология и разведка
Background. The Fan-Yagnob syneclise is an imposed structure within the Hercynian Zeravshan-Gissar zone. It formed on a Paleozoic folded basement as series of sedimentary rocks from T3 to N1, including Jurassic, Cretaceous, and Paleogene terrigenous ...
M. Saymudasiri, A. K. Litvinenko
doaj   +1 more source

Development of a nalmefene formulation suitable for a community‐use auto‐injector

British Journal of Clinical Pharmacology, EarlyView.
Aim Time to onset of reversal is critical when treating opioid‐induced respiratory depression and hypoxia. This study aimed to develop a formulation of the opioid antagonist nalmefene with an increased absorption rate and reduced time to onset of reversal following intramuscular administration. Methods Several absorption enhancers were screened in rats,
Alessandra Cipriano, Manjunath S. Shet, Hugh Huang, Ronnie Ortiz, Garth T. Whiteside, Glen Apseloff, Stephen C. Harris   +6 more
wiley   +1 more source